1 recruiting. 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 1 | Recruiting 1 |
Follow Lixia Sheng: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study of OR for Second-line Treatment of Refractory MZL Orelabrutinib combined with rituximab - OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma | Phase 4 | Recruiting | Lixia Sheng | 39 | 2023-01-02 | 2024-06-11 |
Lymphoma, B-Cell, Marginal Zone (1)
Rituximab (1)
China (1)